Melbourne, Nov 16, 2010 (ABN Newswire) - Regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) announced that positive preclinical trial results were today presented at the American Heart Association's annual conference in Chicago showing that the company's proprietary allogeneic (or "off-the-shelf") stem cells can be injected simply, safely, and effectively into the coronary arteries after a heart attack to prevent heart failure.
